Melanotan 2 before after: Frequently asked questions

Uneven pigmentation reflects heterogeneous MC1R receptor distribution, which is completely normal in fair-skinned phenotypes. Freckling intensifies during weeks 2–4 as the peptide activates melanocytes in localized clusters before dendritic expansion allows melanin transfer to surrounding keratinocytes. Continue the protocol. Patchy pigmentation typically evens out by week six as melanocyte branching catches up. If freckling persists beyond eight weeks, reduce UV exposure duration per session (10 minutes instead of 20) and extend the interval between injections (every 36 hours instead of daily) to allow slower, more uniform melanin deposition.

Melanin produced during the protocol fades at the natural keratinocyte turnover rate, which is approximately 28–40 days. You'll lose 30–50% of endpoint pigmentation within 8–12 weeks of stopping injections and UV exposure. The fade isn't linear. Initial darkening loss is rapid (weeks 1–4 post-cessation), then plateaus as the remaining melanin stabilizes. Most users retain 1–2 shades darker than pre-protocol baseline even six months later, because MT-2 induces lasting increases in melanocyte dendricity that don't fully revert. If you want to preserve results, transition to maintenance dosing (0.5–1mg twice weekly with minimal UV) rather than stopping abruptly.

Most commercial photo galleries omit critical protocol variables: total cumulative dose, exact UV exposure timing and duration, concurrent use of tanning accelerators (psoralen compounds, tyrosine supplements), and post-processing filters or lighting adjustments. The dramatic bronzed appearance in many promotional images involves tanning bed overuse independent of the peptide. 20-minute daily sessions at high UVA intensity will darken skin with or without MT-2, but at significant photoaging cost. Replicate academic trial protocols instead: 0.5–1mg daily for 7–14 days, 10–15 minute natural sunlight exposure 2–4 hours post-injection, and weekly progress photos under identical lighting. That approach produces the 2–5 shade range documented in peer-reviewed dermatology literature.

Verify subcutaneous injection technique first. Shallow injections deposit MT-2 into adipose tissue where absorption is delayed and erratic, blunting MC1R activation. Type I skin has the lowest melanocyte density of all phenotypes, meaning the peptide's effect is inherently weaker and slower. If injection technique is correct and you've completed 14 days at 0.5mg daily with 15-minute UVB sessions 2–4 hours post-injection, extend the loading phase to 21 days before increasing dose. Melanocyte proliferation in pale skin requires more time to establish visible pigment transfer.

Uneven tanning reflects localized melanocyte density variation or inconsistent UV exposure patterns. Face and shoulders typically darken faster than torso due to higher MC1R receptor concentration in sun-exposed skin. Rotate UV exposure to cover all areas evenly, and avoid spot-treating specific body parts with additional peptide. Systemic circulation distributes MT-2 uniformly, so injection site doesn't determine tanning location.

Reduce dose by 50% immediately and reassess tolerance after three injections at the lower amount. Persistent nausea indicates MC4R overstimulation in the area postrema (the brainstem's chemoreceptor trigger zone). Most users adapt within 5–7 days at a given dose, so nausea extending past 10 days suggests the dose exceeds your individual tolerance threshold. Consider splitting daily dose into two smaller injections 8–12 hours apart to blunt peak plasma concentration.

Increase UV exposure first, not dose. MT-2 primes melanocytes but requires UV activation to produce visible pigment. Injecting higher doses without sun or tanning bed sessions won't deepen color. Add 5–10 minute controlled UV sessions 2–3 times weekly and reassess after one additional week. If still no change, verify peptide purity and storage conditions (lyophilized powder stored at 2–8°C, reconstituted solution used within 30 days).

Transition to maintenance dosing at 0.25–0.5mg twice weekly once plateau pigmentation is achieved (typically week 4–6). This sustains MC1R activation without the cumulative dose escalation that increases side effect risk. Maintenance requires occasional UV exposure (1–2 sessions weekly) to preserve active melanin distribution. Without UV, even maintenance dosing won't prevent gradual fading over 4–8 weeks.

This is a documented effect of melanocyte hyperactivation in pigmented lesions and typically does not reverse after stopping MT-2. If cosmetically concerning, discontinue use and consult a dermatologist for lesion assessment. Any mole showing irregular borders, asymmetry, or rapid size change requires professional evaluation regardless of peptide use. MT-2 does not cause melanoma, but it can darken pre-existing lesions, making visual monitoring more difficult.